Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA2 | P00918 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 8/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.39 |
| ▸ | CA12 | O43570 | 3/20 | 0.39 |
| ▸ | CA7 | P43166 | 3/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.39 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.39 |
| ▸ | CA3 | P07451 | 2/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA6 | P23280 | 2/20 | 0.39 |
| ▸ | CA5A | P35218 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.39 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.37 |
| ▸ | THRB | P10828 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL18394656 | 1.00 | CA1 (0.39) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL10626082 | 0.98 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL28644993 | 0.98 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL28468879 | 0.98 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL1817037 | 0.98 | CA1 (0.40) | CA1CA2CA9LPAR3CA12 | |
| SCHEMBL9124098 | 0.88 | ADRB2 (0.43) | CA1CA2CA9SMPD1TSHR | |
| Bromide SCHEMBL29050094 | 0.87 | GBA1 (0.38) | LPAR3LPAR1LPAR2DNM1SMPD1 | |
| SCHEMBL27094088 | 0.86 | LPAR3 (0.46) | LPAR3LPAR1LPAR2MEN1KMT2A | |
| SCHEMBL8440337 | 0.78 | DNM1 (0.46) | CA1CA2CA9CA12CA7 | |
| SCHEMBL6928943 | 0.78 | CA1 (0.31) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1766094-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | Vical Incorporated (US) | 2007-03-28 | — | — | EP | claimed |
| EP-1575505-A4 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | VICAL INC (US) | 2007-01-24 | — | — | EP | claimed |
| WO-2005116270-A2 | INFLUENZA VIRUS VACCINE COMPOSITION AND METHOD OF USE | VICAL INCORPORATED (US) | 2005-12-08 | — | — | WO | claimed |
| EP-1575505-A2 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | Vical Incorporated (US) | 2005-09-21 | — | — | EP | claimed |
| EP-1575505-A3 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | Vical Incorporated (US) | 2005-09-01 | — | — | EP | claimed |
| WO-2004024067-A2 | CODON-OPTIMIZED POLYNUCLEOTIDE-BASED VACCINES AGAINST BACILLUS ANTHRACIS INFECTION | VICAL INCORPORATED (US) | 2004-03-25 | — | — | WO | claimed |
| US-20250376674-A1 | SPLIT PRIME EDITORS | PRIME MEDICINE INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-12454694-B2 | Compositions and methods for improving base editing | BEAM THERAPEUTICS INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250179483-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE 1B | PRIME MEDICINE, INC. | 2025-06-05 | — | — | US | disclosed |
| US-20250073352-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF FRAGILE X SYNDROME | PRIME MEDICINE, INC. | 2025-03-06 | — | — | US | disclosed |
| US-20240417706-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | EDITAS MEDICINE, INC. (US) | 2024-12-19 | — | — | US | disclosed |
| US-20240352453-A1 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF RETINOPATHY | PRIME MEDICINE, INC. | 2024-10-24 | — | — | US | disclosed |
| US-20240301405-A1 | GUIDE RNAS FOR CRISPR/CAS EDITING SYSTEMS | BEAM THERAPEUTICS INC. | 2024-09-12 | — | — | US | disclosed |
| US-10006054-B1 | Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA | EDITAS MEDICINE, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-20180119123-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS | EDITAS MEDICINE, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| WO-2017075475-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS | EDITAS MEDICINE, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170029850-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA | EDITAS MEDICINE, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170022507-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING CYSTIC FIBROSIS | EDITAS MEDICINE, INC. (US) | 2017-01-26 | — | — | US | disclosed |
| EP-1278551-A2 | COMPOSITIONS AND METHODS FOR (IN VIVO) DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2003-01-29 | — | — | EP | disclosed |
| WO-2001080897-A2 | COMPOSITIONS AND METHODS FOR IN VIVO DELIVERY OF POLYNUCLEOTIDE-BASED THERAPEUTICS | VICAL INCORPORATED (US) | 2001-11-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301405-A1 | GUIDE RNAS FOR CRISPR/CAS EDITING SYSTEMS | NSUN3, ZFR, NARS1 | CA1 4271/4885CA2 4621/4885CA9 4042/4885 |
| US-20180119123-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS | CCR5, CXCR4, CXCR3 | CA1 4519/4885CA2 3285/4885CA9 2430/4885 |
| US-20170029850-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING PRIMARY OPEN ANGLE GLAUCOMA | UACA, CRYAA, CRYAB | CA1 3988/4885CA2 184/4885CA9 168/4885 |
| US-20240417706-A1 | SYSTEMS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HBG2, HBG1, HBB | CA1 4705/4885CA2 3824/4885CA9 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.